top of page
![shutterstock_756403858-[Converted].png](https://static.wixstatic.com/media/751e53_f24d109a5ec44806861464b65e3b8904~mv2.png/v1/fill/w_49,h_28,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/751e53_f24d109a5ec44806861464b65e3b8904~mv2.png)
We are a
Life Sciences Company that Cares
We are transforming the drug discovery and development process and accelerating the creation of life-changing psilocybin drugs on behalf of patients.
Our Focus is to provide objective, quantitative diagnoses and monitoring for some of the world’s most prevalent diseases including:
ALZHEIMER'S & DEMENTIA
+LEARN MORE BELOW
CSE: MYND / OTC: MYNDF
We Remember Their Love When They No Longer Do
What if we told you we could diagnose early-onset dementia sooner and more accurately?
Dare to Think Differently?
Understanding
Alzheimer's
Alzheimer's Disease (AD) is a cognitive deterioration beyond the normal consequences of ageing. As the 7th leading cause of death worldwide, AD contributes significant social, economic and personal impacts. Most, if not all of us, will, unfortunately, know someone battling AD.
Early & Correct
Diagnosis is Key
Currently, the only way to diagnose AD is through a combination of several subjective tests and questionnaires that may rule out other illnesses.
We are developing a Biomarker test that will objectively detect the presence of a certain protein in the blood that needs to be present to fight the inflammation that causes AD. Clinical validation by collecting known blood samples of AD and qualifying the presence of the Biomarker against controlled samples. This will potentially provide a more accurate and objective diagnosis for AD and will pave the way for early and accurate treatment protocols.
As AD advances, symptoms get more severe and include disorientation, confusion and behaviour changes. Eventually, speaking, swallowing and walking become difficult. Early detection is essential for effective treatment. Greater awareness and understanding can lead to better outcomes.
We have designed a Biomarker that potentially can early identify AD.
Prolonged suffering no longer needs to be the diagnosis.
Alzheimer's kills more people that Breast Cancer & Prostate Cancer combined.
Through our clinical trials we anticipate being able to diagnose with our biomarker and eventually our drug candidates will provide a pathway to getting better.
Welcome to the future, where the reconnection of lost pathways is a possibility, are you ready to heal your mynd?
Alzheimer's Disease isn’t the only thing on our Mynd. Explore our other groundbreaking initiatives on neuroinflammatory diseases.
WHAT'S IN OUR PIPELINE?
Press Releases
Interviews
Stay Informed on Key Developments
bottom of page